Grufity logoGrufity logo
StocksFundsSearch Filings

Arcus Biosciences Inc Stock Research

RCUS

20.54USD+0.28(+1.38%)Market Closed

Market Summary

USD20.54+0.28
Market Closed
1.38%

RCUS Alerts

RCUS Stock Price

RCUS RSI Chart

RCUS Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

-5.38

Price/Sales (Trailing)

12.62

EV/EBITDA

-4.67

Price/Free Cashflow

-4.69

RCUS Price/Sales (Trailing)

RCUS Profitability

EBT Margin

-237.50%

Return on Equity

-40.64%

Return on Assets

-19.85%

Free Cashflow Yield

-21.33%

RCUS Fundamentals

RCUS Revenue

Revenue (TTM)

119.0M

Revenue Y/Y

38.85%

Revenue Q/Q

-25.72%

RCUS Earnings

Earnings (TTM)

-279.0M

Earnings Y/Y

-17.66%

Earnings Q/Q

-18.6%

Price Action

52 Week Range

15.7036.13
(Low)(High)

Last 7 days

13.8%

Last 30 days

11.4%

Last 90 days

16.9%

Trailing 12 Months

8.4%

RCUS Financial Health

Current Ratio

5.53

RCUS Investor Care

Shares Dilution (1Y)

2.06%

Peers (Alternatives to Arcus Biosciences)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
117.9B
26.2B
-7.64% -12.03%
14.89
4.5
-0.48% 38.34%
96.0B
27.0B
-5.50% 23.66%
17.2
3.55
-1.56% 23.65%
49.0B
15.1B
-4.27% -12.12%
10.25
3.26
-33.37% -67.32%
42.8B
10.1B
-4.73% 48.21%
13.67
4.24
-6.61% 115.98%
MID-CAP
8.7B
1.6B
-13.93% -4.24%
136.39
5.46
32.38% -10.36%
4.1B
-
17.13% 24.41%
-11.15
38.1
122.90% -29.67%
2.4B
76.7M
3.81% -9.32%
-7.51
30.96
41.73% -32.75%
2.2B
107.9M
-4.32% 100.88%
-4.54
20.39
54.84% 17.36%
SMALL-CAP
1.5B
119.0M
11.39% 8.39%
-5.38
12.62
-69.61% -584.39%
1.1B
10.0M
8.51% 30.70%
-6.18
107.56
215.65% -47.65%
694.6M
-
4.27% -85.45%
-0.6
0.35
72.89% 12.32%
495.9M
136.9M
-20.60% -78.14%
-2.11
3.62
116.83% -0.93%
186.8M
241.0M
-25.83% -69.32%
-1.47
0.78
113.96% 27.87%
165.4M
697.0K
50.34% -66.48%
-1.53
237.34
47.98% -35.48%
8.7M
-
-35.78% -88.38%
-0.11
3.21
0.51% -129.47%

Financials for Arcus Biosciences

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue6.2%119112433409392
Operating Expenses6.6%418392358342332
  S&GA Expenses5.8%11010499.0089.0080.00
  R&D Expenses6.9%308288258253252
EBITDA-392.3%-26089.0075.00-281-
EBITDA Margin-1230.1%-2.32*0.21*0.18*-0.72*-
Earnings Before Taxes-4.1%-277-26683.0070.0061.00
EBT Margin-1338.9%-2.37*0.19*0.17*-0.73*-
Net Income-4.5%-279-26780.0067.0058.00
Net Income Margin-1390.3%-2.38*0.18*0.16*0.15*-
Free Cahsflow0.1%432432452439-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-6.8%1,2541,3451,3941,4771,543
  Current Assets-4.9%1,0151,0671,1011,2271,264
    Cash Equivalents15.5%238206218273549
  Net PPE5.7%37.0035.0034.0033.0033.00
Liabilities-4.7%695729747--
  Current Liabilities-7.3%179193177164161
Shareholder's Equity-8.7%600657699747797
  Retained Earnings-14.8%-622-542-474-409-343
  Additional Paid-In Capital1.6%1,1831,1651,145--
Shares Outstanding0.3%73.0073.0072.0072.0072.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-171.7%-314438446473464
  Share Based Compensation3.8%67.0065.0063.0061.0059.00
Cashflow From Investing96.1%-15.94-413-441-553-334
Cashflow From Financing-42.2%19.0033.0033.0032.0030.00

Risks for RCUS

What is the probability of a big loss on RCUS?

100%


Probability that Arcus Biosciences stock will be more than 20% underwater in next one year

100%


Probability that Arcus Biosciences stock will be more than 30% underwater in next one year.

88.5%


Probability that Arcus Biosciences stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RCUS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Arcus Biosciences was unfortunately bought at previous high price.

Drawdowns

Returns for RCUS

Cumulative Returns on RCUS

5.8%


5-Year Cumulative Returns

-13.1%


3-Year Cumulative Returns

What are the long-term rolling returns for RCUS?

FIve years rolling returns for Arcus Biosciences.

Annualized Returns

Which funds bought or sold RCUS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-23
Capital Impact Advisors, LLC
added
26.89
39,811
373,938
0.46%
2023-05-22
PUTNAM INVESTMENTS LLC
sold off
-100
-2,722,130
-
-%
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-4.44
-664,562
3,557,440
-%
2023-05-19
Coppell Advisory Solutions LLC
sold off
-100
-4,136
-
-%
2023-05-18
JPMORGAN CHASE & CO
added
4.87
-798,000
9,850,000
-%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-5.39
-179,000
902,000
-%
2023-05-17
VIRGINIA RETIREMENT SYSTEMS ET AL
added
23.38
-25,904
1,025,730
0.01%
2023-05-17
Thrivent Financial for Lutherans
reduced
-3.39
-164,000
942,000
-%
2023-05-16
Hudson Bay Capital Management LP
added
359
3,153,900
4,187,900
0.02%
2023-05-16
Kiwi Wealth Investments Limited Partnership
unchanged
-
-135,198
1,010,660
0.07%

1–10 of 43

Latest Funds Activity

Are funds buying RCUS calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own RCUS
No. of Funds

Arcus Biosciences News

Simply Wall St
General Mills (NYSE:GIS) Seems To Use Debt Quite Sensibly.
Simply Wall St,
77 minutes ago
The Pharma Letter
What to look out for at ASCO 2023.
The Pharma Letter,
21 hours ago
Defense World
Investor's Business Daily
Simply Wall St

Schedule 13G FIlings of Arcus Biosciences

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
biotechnology value fund l p
1.7%
1,236,002
SC 13G/A
Feb 14, 2023
pfm health sciences, lp
3.7%
6
SC 13G/A
Feb 09, 2023
vanguard group inc
6.04%
4,373,177
SC 13G
Jan 26, 2023
blackrock inc.
13.0%
9,389,048
SC 13G/A
Jan 20, 2023
blackrock inc.
13.0%
9,389,048
SC 13G/A
Oct 17, 2022
pfm health sciences, lp
5.5%
6
SC 13G
May 09, 2022
blackrock inc.
11.1%
7,967,677
SC 13G
Mar 14, 2022
biotechnology value fund l p
3.0%
2,156,510
SC 13G
Feb 14, 2022
ecor1 capital, llc
7.9%
5,523,358
SC 13G/A
Feb 14, 2022
pfm health sciences, lp
4.9%
6
SC 13G/A

RCUS Fair Value

Show Fair-Value

Recent SEC filings of Arcus Biosciences

View All Filings
Date Filed Form Type Document
May 15, 2023
8-K
Current Report
May 09, 2023
8-K
Current Report
May 09, 2023
10-Q
Quarterly Report
Apr 25, 2023
ARS
ARS
Apr 21, 2023
DEFA14A
DEFA14A
Apr 21, 2023
DEF 14A
DEF 14A
Mar 20, 2023
4
Insider Trading
Mar 10, 2023
8-K
Current Report
Mar 10, 2023
3
Insider Trading
Feb 28, 2023
S-8
Employee Benefits Plan

Latest Insider Trading transactions for RCUS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-16
Jarrett Jennifer
sold
-146,734
16.81
-8,729
chief operating officer
2023-01-27
Jarrett Jennifer
sold
-37,632
23.52
-1,600
chief operating officer
2023-01-26
Jarrett Jennifer
sold
-7,068
23.56
-300
chief operating officer
2023-01-23
ROSEN TERRY J
acquired
-
-
105,700
chief executive officer
2023-01-23
Nuyten Dimitry SA
acquired
-
-
34,000
chief medical officer
2023-01-23
Goeltz II Robert C.
acquired
-
-
34,000
chief financial officer
2023-01-23
Jarrett Jennifer
acquired
-
-
45,800
chief operating officer
2023-01-23
Jaen Juan C.
acquired
-
-
45,800
president
2023-01-23
Tang Carolyn C.
acquired
-
-
34,000
general counsel
2022-12-16
Jaen Juan C.
sold
-136,407
30.7501
-4,436
president

1–10 of 50

Terry J. Rosen
370
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

RCUS Income Statement

2023-03-31
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenues:  
Total revenues$ 25$ 18
Operating expenses:  
Research and development (Net of recoveries of $33 and $30 from a related party)8161
General and administrative3024
Total operating expenses11185
Loss from operations(86)(67)
Non-operating income (expense):  
Interest and other income, net9 
Effective interest on liability for sale of future royalties(1) 
Total non-operating income, net8 
Loss before income taxes(78)(67)
Income tax expense(2)(1)
Net loss$ (80)$ (68)
Net loss per share, basic$ (1.09)$ (0.96)
Net loss per share, diluted$ (1.09)$ (0.96)
Shares used to compute net income loss per share, basic73.071.2
Shares used to compute net income loss per share, diluted73.071.2
License and Development Services Revenue  
Revenues:  
Total revenues$ 17$ 8
Other Collaboration Revenue  
Revenues:  
Total revenues$ 8$ 10

RCUS Balance Sheet

2023-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 238$ 206
Marketable securities716803
Receivable from collaboration partners ($33 and $39 from a related party)3339
Prepaid expenses and other current assets2819
Total current assets1,0151,067
Long-term marketable securities90129
Property and equipment, net3735
Other noncurrent assets ($3 and $2 from a related party)112114
Total assets1,2541,345
Current liabilities:  
Accounts payable2820
Deferred revenue ($97 and $97 to a related party)9797
Other current liabilities5476
Total current liabilities179193
Deferred revenue, noncurrent ($330 and $355 to a related party)330355
Other noncurrent liabilities145140
Commitments
Stockholders’ equity:  
Preferred stock, $0.0001 par value per share; 10.0 shares authorized; no shares issued and outstanding00
Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 73.1 shares in 2023 and 72.9 shares in 2022 issued and outstanding1,2261,206
Accumulated deficit(622)(542)
Accumulated other comprehensive loss(4)(7)
Total stockholders’ equity600657
Total liabilities and stockholders’ equity$ 1,254$ 1,345